Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative

symbol logo$EBS Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.36 down -131.30% YoY • Reported revenue of $110M down -52.40% YoY • Emergent BioSolutions revised its full-year 2026 forecast to total revenues of $600M, net loss of -$255M, adjusted EBITDA of $110M, and adjusted gross margin of 45%-47%.
1

Price since post

Full Details

Advertisement|Remove ads.